A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination with Pembrolizumab in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

MC #19-09

NCT #
NCT03881488
Condition(s)
Lung Cancer (NSCLC), Lung Cancer (SCLC), Skin Cancer/ Melanoma
Molecular Target(s)
CD137, PD-1, PD-L1
Drug Classification(s)
Monoclonal Antibody, Targeted Therapy
Agents(s)
CTX-471
Phase(s)
I

Mechanism of Action

CTX-471 is a fully humanized IgG4 agonist antibody for CD-137, also known as 4-1BB, a costimulatory factor for T cells and NK cells.

Purpose

  • How much of the study agent alone or in combination with Pembrolizumab can be given with an acceptable level of side effects
  • Learn about the safety and tolerability of the study agent
  • How much of the study agent alone or in combination with Pembrolizumab is absorbed into the blood and how fast it is removed
  • How proteins that indicate the status of your disease are affected with the use of the study agent alone or in combination with Pembrolizumab
  • If your body develops proteins that work against the study agent alone or in combination with Pembrolizumab
  • If research tests can be used in the future to predict who will benefit from CTX-471

Location

MCD

Similar Trials

Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Trispecific Antibodies
Yes
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
MCD
JIT-MCLA-128-CL01
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
n/a
NRG1 fusion
Lung Cancer (NSCLC), Pancreatic Cancer
MCD
JIT-MCLA-129-CL01
MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody
n/a
EGFR, MET
Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC)
MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.